PCR Quantitation of Fetal Cells in Maternal Blood in Normal and Aneuploid Pregnancies**Presented in part at the annual meeting of the Society for Pediatric Research, Washington, DC, May 7, 1996, and at the 46th meeting of the American Society of Human Genetics, San Francisco, October 31, 1996.  by Bianchi, Diana W. et al.
Am. J. Hum. Genet. 61:822–829, 1997
PCR Quantitation of Fetal Cells in Maternal Blood in Normal and
Aneuploid Pregnancies*
Diana W. Bianchi,1 John M. Williams,3 Lisa M. Sullivan,2 Frederick W. Hanson,4
Katherine W. Klinger,5 and Anthony P. Shuber5
1Departments of Pediatrics, Obstetrics and Gynecology, New England Medical Center and Tufts University School of Medicine, and 2Section
of General Internal Medicine Research Unit, Boston Medical Center, Boston; 3Genzyme Corporation, Cambridge, MA; 4The Prenatal
Diagnostic and Imaging Center, Sacramento; and 5Genzyme Genetics, Framingham, MA
Summary Introduction
Fetal cells in maternal blood are a noninvasive source Feto-maternal transfusion of erythrocytes, with its con-
of fetal genetic material for prenatal diagnosis. We deter- sequence of maternal alloimmunization and fetal ane-
mined the number of fetal-cell DNA equivalents present mia, has been appreciated since the 1940s (Allen 1982).
in maternal whole-blood samples to deduce whether this The opportunity to use these transfused fetal cells for
number is affected by fetal karyotype. Peripheral blood noninvasive prenatal cytogenetic diagnosis has only re-
samples were obtained from 199 women carrying chro- cently been realized (Price et al. 1991; Bianchi et al.
mosomally normal fetuses and from 31 women with 1992; Simpson and Elias 1993; Ga¨nshirt-Ahlert et al.
male aneuploid fetuses. Male fetal-cell DNA-equivalent 1993; Bianchi 1995). Currently, invasive prenatal diag-
quantitation was determined by PCR ampliﬁcation of a nostic procedures such as chorionic-villus sampling and
Y chromosome–speciﬁc sequence and was compared amniocentesis are usually offered to women ú35 years
with PCR product ampliﬁed from known concentrations of age, in the absence of speciﬁc fetal abnormalities,
of male DNA run simultaneously. The mean number of positive family history, or other indications of elevated
male fetal-cell DNA equivalents detected in 16-ml blood risk. Screening on the basis of maternal age detects
samples from 90 women bearing a 46,XY fetus was 19 õ20% of fetuses with trisomy 21 (Verloes et al. 1995),
(range 0–91). The mean number of male fetal-cell DNA whereas measurement of maternal serum alpha-feto-
equivalents detected in 109 women bearing a 46,XX protein, human chorionic gonadotropin, and unconju-
fetus was 2 (range 0–24). The mean number of male gated estriol detects 65% of fetuses with trisomy 21, at
fetal-cell DNA equivalents detected when the fetus was a calculated false-positive rate of 5% (Wald et al. 1995).
male compared with when the fetus was female was As an alternative, we and others are exploring the
highly signiﬁcant (P Å .0001). More fetal cells were feasibility and clinical applicability of screening for com-
detected in maternal blood when the fetus was aneu- mon fetal aneuploidies by performing FISH analysis of
ploid. The mean number of male fetal-cell DNA equiva- interphase fetal cells circulating in maternal blood. The
lents detected when the fetal karyotype was 47,XY,/21 sensitivity and speciﬁcity of this approach is presently
was 110 (range 0.1–650), which was signiﬁcantly higher being addressed in a multicenter clinical trial that is
than the number of male fetal-cell DNA equivalents de- supported by the National Institutes of Health (de la
tected in 46,XY fetuses (P Å .0001). Feto-maternal Cruz et al. 1995).
transfusion of nucleated cells appears to be inﬂuenced Review of the published literature has suggested that
by fetal karyotype. The sixfold elevation of fetal cells variable numbers of fetal cells are detectable in maternal
observed in maternal blood when the fetus had trisomy blood, range 3–74, in 15–40-ml maternal blood sam-
21 indicates that noninvasive cytogenetic diagnosis of ples (Elias et al. 1992; Wessman et al. 1992; Hawes et
trisomy 21 should be feasible. al. 1994; Reading et al. 1995; Takabayashi et al. 1995).
Our own studies, performed on 20-ml maternal venous
blood samples, obtained from women with cytogeneti-
cally normal fetuses and enriched for the presence of
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et al. 1992; Ga¨nshirt-Ahlert et al. 1993). Because of Validation of Whole-Blood–PCR Method
the relatively small numbers of patients studied in each Three separate experiments were performed, with two
report, it was impossible to determine whether the dis- to ﬁve replicates (35 total samples) of small numbers (0,
crepancies were due to laboratory technique, patient 25, 50, or 100) of either Raji cells (a male B-lymphoblas-
population, or other, unknown factors. The purpose of toid cell line), male fetal nucleated blood cells, or male
the present study, therefore, was to determine as accu- fetal liver cells (Advanced Biosciences Resources), mixed
rately as possible the number of fetal cells circulating in into 8 ml of adult female peripheral blood. No difference
maternal whole-blood samples, thereby deducing in quantitation of male fetal-cell DNA equivalents was
whether this number is inﬂuenced primarily by fetal observed by the PCR method, on the basis of the type of
karyotype, which affects the biology of the fetoplacental model fetal cell employed (data not shown). Additional
unit, or by laboratory method of cell separation. To samples containing 0, 5, 10, 25, 50, or 100 Raji cells
perform the work, we developed a technique of quanti- were then subjected to DNA extraction and ampliﬁca-
tation of male fetal-cell DNA equivalents, using PCR tion conditions, followed by quantitation of Y DNA and
ampliﬁcation of maternal venous blood samples. Our statistical analysis, and were compared with ﬂuorescent-
results, based on a large study sample, suggest that fetal microscopy enumeration of Hoechst 33342–stained nu-
cells are present at low levels when the fetus has a nor- clei in the constructed cell mixture.
mal karyotype and that increased feto-maternal transfu-
PCRsion of nucleated cells occurs when the fetus has a chro-
mosome abnormality. The contents of each 8-ml vacutainer tube were mixed
with 30 ml of 1 1 erythrocyte lysis buffer (ELB) (10
1 ELB Å 82.9 g of NH4Cl, 10.0 g KHC03, and 0.2 g
Material and Methods of EDTA in 1 liter of dH20, pH Å 7.4) and were centri-
fuged, and the supernatant was discarded twice. The
Maternal Blood Samples remaining pellet was resuspended in nuclear lysis buffer
A total of 230 venous blood samples were studied. (5 ml of 1 M Tris pH 7.5, 40 ml of 5 M NaCl, 2 ml of
Study patients were recruited from clinical sites all over 0.5 M EDTA, and 453 ml of dH20) with 660 ml of
the United States. All women underwent prenatal cyto- 10% SDS solution and 1.65 ml of 20 mg proteinase K
genetic diagnosis either by amniocentesis (226 cases) or solution/ml and was kept at 37C overnight and then
chorionic villus sampling (CVS) (4 cases). In 199 sam- was subjected to high salt extraction and precipitation
ples, the fetus had a normal karyotype. Of these, 190 using isopropanol and to further puriﬁcation using a
were obtained preamniocentesis, and 9 were obtained 50% solution of Chelex resin (Bio-Rad). Final resuspen-
postamniocentesis. In samples obtained from 31 preg- sion occurred in 2 ml of Tris-EDTA buffer. Extreme
nant women, the fetal karyotype was abnormal and caution was observed, to prevent introduction of pre-
male. Four of these samples were obtained preproce- viously ampliﬁed product into the maternal DNA.
dure, and 27 were obtained postprocedure, at the time Because the Y chromosome is absent in the mother,
when the women were receiving genetic counseling re- it was chosen as a marker to quantify the number of
garding the abnormal diagnosis. Of the 27 samples ob- male fetal-cell DNA equivalents originating in male fe-
tained postprocedure, 4 were drawn post-CVS (mean tuses. PCR was performed by use of the primers 49a-06-
12.8 d, range 7–20 d), and 23 were drawn postamnio- Y (5-CTT/TCT/TTT/CAG/GCA/TTT/CCT/GCT/TAT-
centesis (mean 14.6 d, range 5–55 d). 3)and 49a-07-Y (5-GTT/CTA/CAG/AAA/AGT/TAT/
After informed consent was obtained under a protocol TGC/CAA/GTA-3), which map to the long arm of the
approved by New England Medical Center and collabo- Y chromosome (Lucotte et al. 1991). The total reaction
rating institutions, Ç16 ml of blood were drawn into volume consisted of 10 ml of ‘‘hot start’’ premix (8 ml
two vacutainer tubes containing acid citrate dextrose of dH20, 1 ml of 1 1 Taq buffer, and 1 ml of Taq poly-
solution A (ACDA) as an anticoagulant. In all cases, merase), 10 ml of DNA, 21 ml of dH20, 4 ml 10 1 Taq
gestational age of the fetus was conﬁrmed by sono- buffer, 2.5 ml of 20 1 dNTPs, 2 ml of 10 mM Y primers,
graphic examination. In the 199 fetuses with a normal and 0.5 ml of 32P dCTP. Ampliﬁcation consisted of 10–
karyotype, blood samples were processed and results 30 min at 95C, followed by 34 cycles at 95C for 30
analyzed without prior knowledge of fetal gender. Fetal s, 55C for 30 s, and 74C for 30 s, followed by a
karyotype was conﬁrmed in the referring physician’s of- 15C holding temperature. For each reaction, a standard
ﬁce, on a minimum of two separate occasions. When a curve was run simultaneously with known amounts of
discrepancy in the fetal gender was noted between the added male genomic DNA (50–400 pg). Ampliﬁed
two reports, a third veriﬁcation was requested, with the product was separated by electrophoresis in a 2%
infant’s gender subsequently being conﬁrmed at birth. Seakem ME agarose gel, at 175 mA constant current
In all cases the discrepancies were due to secretarial for 11/2 h. The gel was then dried and was exposed
to the phosphorimager screen for 25 min, followed bytranscription error, not cytogenetic laboratory error.
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exposure to x-ray ﬁlm for 2–6 h at 080C. Results were
quantitated by use of a phosphorimager (Molecular Dy-
namics). Average counts per minute (cpm) were deter-
mined for each reaction product by drawing a rectangle
around the largest band and subtracting the background
cpm in the reaction blanks. The number of cpm in the
Figure 2 Autoradiograph of ampliﬁed PCR product and maletest samples was either plotted directly against the curve
standard DNA used for quantitation. These reactions were run simul-of the ampliﬁed product in the male standard DNA or
taneously. Lanes 1 and 4 represent aliquots from the same maternalcalculated by use of a factor derived from the number
sample, with 13 and 16 male fetal-cell DNA equivalents detected in
of cpm measured divided by the number of picograms the respective lanes. Lane 2 represents a negative control with no
of male standard DNA and was converted to a cell num- added male cells (0 male cells detected). Lane 3 represents a positive
control with 142 male cells detected. Lanes 5–8 represent productsber by use of the formula 5 pg of DNA/cell. Results were
generated from known amounts (50–400 pg) of male DNA.reported per 8-ml tube of blood and were extrapolated
upward or downward to the equivalent of 16 ml if more
or less blood originally had been taken from the patient.
bution of the number of male fetal-cell DNA equivalents
Statistical Analysis was not normal, we also investigated nonparametric
Statistical analyses were performed by use of Statisti- tests. In all cases the results of the parametric and non-
cal Analysis Software (SAS). In the ﬁrst phase of analy- parametric tests were consistent. Thus, results of the
sis, descriptive statistics were generated for all study parametric tests are presented here. Finally, gestational
variables. Graphical analyses were utilized to under- age and whether the sample was obtained pre- or postin-
stand the distributional properties of study variables. vasive procedure were considered as covariates. The re-
In the second phase, a series of statistical tests were lationship between gestational age and the number of
performed. Two-independent-samples t-tests were used male cells detected was evaluated by use of correlation
to examine differences, in the mean number of male analysis, and the relationship between whether the sam-
cells detected, between normal karyotypes. Analysis of ple was obtained pre- or postprocedure and the number
variance (ANOVA) was used to test for differences, in of male cells detected was evaluated by use of two-inde-
the mean numbers of male cells detected, among abnor- pendent-samples t-tests and ANOVA.
mal karyotypes, and least-squares means were compared
to assess signiﬁcance between pairs of abnormal karyo- Results
types. Although the two-independent-samples t-test has
been shown to be robust in the presence of skewed distri- Quantitation in Constructed Cell Mixtures
butions (Sullivan and D’Agostino 1992), since the distri- The sensitivity and accuracy of PCR quantitation of
male fetal-cell DNA equivalents in whole blood was
determined on constructed cell mixtures. These artiﬁcial
cell mixtures were designed to mimic a small feto-mater-
nal hemorrhage and consisted of the same volume of
blood processed for bona ﬁde maternal samples. A cor-
relation coefﬁcient of .89 was observed for the number
of male fetal-cell DNA equivalents detected by PCR and
the estimated number of cells spiked into constructed
cell mixtures (ﬁg. 1).
Quantitation in Normal Pregnancies
Of the 199 samples obtained from women with cyto-
genetically normal prenatal karyotypes, 90 carried
46,XY fetuses and 109 carried 46,XX fetuses. Figure 2
demonstrates the ampliﬁed products used for quantita-
tion. The mean number of male fetal-cell DNA equiva-
lents detected in the samples obtained from the 90
women bearing 46,XY fetuses was 19 (range 0–91).
Eighty-four percent of women carrying a 46,XY fetus
had detectable male DNA at the level of §2 cell equiva-
Figure 1 Dot plot demonstrating relationship between number
lents (table 1 and ﬁg. 3). An additional 15.3% of womenof nucleated male cells in artiﬁcial mixture (x- axis), as determined
had male DNA detected in them, but it was at the levelby ﬂuorescent-microscopic enumeration, and average number of male-
cell DNA equivalents, as detected by PCR (y-axis). of õ2 cell equivalents. The mean number of male cells
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Table 1
Distribution of Number of Cells Detected, According to Karyotype
PROPORTION IN WHICH NO. OF DETECTED MALE-CELL DNA EQUIVALENTS Åa
(%)
KARYOTYPE .0–2.0 2.1–5.0 5.1–10.0 10.1–25.0 §25.1
46,XX 74.3 11.0 11.0 3.7 0
46,XY 15.6 11.1 22.2 22.2 28.9
47,XY,/21 11.1 0 11.1 11.1 66.7
a Note that, for each karyotype, the row sums to 100%.
detected in the samples drawn from the 109 women Quantitation in Aneuploid Pregnancies
carrying 46,XX fetuses was 2 (range 0–24). The number Signiﬁcantly more fetal-cell DNA equivalents were de-
of male fetal-cell DNA equivalents detected when the tected in blood samples from mothers carrying aneu-
fetus was male versus when the fetus was female was ploid fetuses, compared with mothers carrying normal
highly signiﬁcant (P Å .0001). The mean gestational fetuses (88 vs. 10; PÅ .0001) (ﬁg. 6). The mean numbers
ages at which blood samples were obtained were 15.7 and ranges of male fetal-cell DNA equivalents detected,
and 15.5 wk for 46,XX and 46,XY fetuses, respectively, according to abnormal karyotype, are shown in table 2.
and were not statistically different (P Å .46) (ﬁg. 4). The mean gestational age of the abnormal fetuses was
In male fetuses, no signiﬁcant correlation was observed 18.5 wk, which did signiﬁcantly differ from that of the
between the number of male cells detected and gesta- normal fetuses (P Å .006), although the 3-wk difference
tional age at the time of sampling (11–32 wk) (r is not of clinical importance. After adjustment for gesta-
Å 0.07832; P Å .46). Because amniocentesis could po- tional age, however, the values of the male fetal-cell
tentially cause feto-maternal hemorrhage, samples were DNA equivalents remained highly signiﬁcantly elevated
also analyzed according to when they were obtained. in the abnormal fetuses (P Å .0001). The mean number
No differences were observed in the mean number of of cells detected when the karyotype was 47,XY,/21
male cells detected pre- versus postamniocentesis, in was 110 (range 0.1–650), which was signiﬁcantly higher
46,XX fetuses and 46,XY fetuses (P Å .92 and .25, than the mean number of fetal cells detected in normal
respectively) (ﬁg. 5). male (46,XY) fetuses (P Å .0001). The distribution of
numbers of cells detected in 46,XX and 46,XY fetuses
versus 47,XY,/21 fetuses is given in table 1. Sixty-six
percent of trisomy 21 fetuses had ú25 fetal cells de-
Figure 3 Dot plots demonstrating number of male fetal-cell
DNA equivalents detected in 16-ml maternal samples from women
carrying fetuses with normal karyotypes. The range of the number of
male fetal-cell DNA equivalents detected is shown for 46,XY (left) Figure 4 Number of male-cell DNA equivalents detected, as a
function of gestational age. Data shown are for 46,XY fetuses only.and 46,XX fetuses.
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Figure 5 Bar graph demonstrating mean number of male fetal-cell DNA equivalents detected in 16-ml maternal samples obtained from
women carrying normal fetuses pre- and postamniocentesis. The numbers of samples represented in this graph are as follows: 46,XX-pre, 105;
46,XX-post, 4; 46,XY-pre, 85; and 46,XY-post, 5.
tected. Similarly, the difference between the number and either 47,XY,/13, 47,XXY, or 47,XY,/18. How-
ever, the lack of signiﬁcance may be due to small num-of male fetal-cell DNA equivalents detected in
47,XY,/inv(dup)15 and 46,XY fetuses was also highly bers—and, therefore, low power in the statistical tests.
To ascertain whether inclusion of the samples fromsigniﬁcant (P Å .0001). In pairwise comparisons, no
signiﬁcant differences were observed between 46,XY the four women who underwent CVS biased the data,
Figure 6 Bar graph demonstrating mean number of male fetal-cell DNA equivalents detected in maternal samples, stratiﬁed by fetal
karyotype. Note that the highest number of male fetal-cell DNA equivalents is detected when the fetus has 47,XY,/21 or 47,XY,/inv(dup)15.
The asterisk (*) indicates that the values for 47,XY,/inv(dup)15 are off the scale, with a mean value of 230.
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Table 2 resents the largest population of maternal samples stud-
ied to date by use of a single uniform assay. The data
Number of Male-Cell DNA Equivalents Detected
demonstrate that feto-maternal transfusion of nucleatedin Aneuploid Cases
cells is a common phenomenon but that the mean num-
Fetal Karyotype Mean { SD (Range) of Male-Cell ber of fetal cells detected in a 16-ml sample is perhaps
(No. of Samples) DNA Equivalents Detected lower than previously had been expected. On average,
it appears that Ç1 nucleated fetal-cell DNA equivalent/
47,XY,/21 (18) 110 { 162 (.1–650)
ml of maternal whole blood is present when the fetus47,XY,/18 (6) 20 { 25 (0–58)
has a normal karyotype.47,XY,/13 (2) 38 { 54 (.1–76)
47,XXY (2) 23 { 2 (21–24) The observation that low numbers of male fetal cells
47,XY,/inv(dup)15 (2) 230 { 269 (40–420) could be detected in some blood samples from women
48,XXXY,/inv10 (1) 7 carrying normal female fetuses was unexpected. This
phenomenon was observed in 28/109 (25.7%) of
women carrying female fetuses, although only 16/109
(14.7%) of women had ú5 male cells detected and onlywe analyzed these samples separately. Of the four sam-
4/109 women (3.7%) had§10 fetal cells measured. Pos-ples, three were from women whose fetuses had
sible sources of male cells in the blood samples from47,XY,/21 and one was from a woman whose male
pregnant women include a vanishing-twin gestation,fetus had trisomy 18. The number of male fetal-cell
previous maternal blood transfusions from a male do-DNA equivalents for the ﬁrst three samples was 9, 22,
nor, or the history of a prior pregnancy with a maleand 91, respectively. The number of fetal-cell DNA
fetus. The long-term persistence of fetal CD34/CD38/equivalents for the single 47,XY,/18 sample was 58.
cells postpartum has recently been demonstrated else-As stated above, the mean number of fetal-cell DNA
where (Bianchi et al. 1996). In the current study, noequivalents in all maternal samples carrying fetuses with
information was available regarding the maternal trans-trisomy 21 was 110. Removal of the three post-CVS
fusion history. Review of the prior pregnancy historypatients raised the mean value for trisomy 21 to 123.
was retrospectively ascertained. In women carryingRemoval of the trisomy 18 patient reduced the mean
46,XX fetuses and with no prior history of a male child,for trisomy 18 from 20 to 12. Therefore, inclusion of the
the mean number of male cells detected was 1. In womensamples obtained from women who were postprocedure
carrying 46,XX fetuses, there was also no associationCVS did not signiﬁcantly affect the results and conclu-
between the number of prior male children and the num-sions.
ber of male fetal-cell DNA equivalents detected. Interest-
ingly, however, there was an association between theDiscussion
age of the most recently delivered son and the number
of male fetal-cell DNA equivalents. The women whoWe have described a quantitative fetal-cell DNA-
equivalent assay designed to detect rare numbers of fetal were currently pregnant with female fetuses whose sons
were §8 years of age had the most male cells detected.cells circulating in maternal blood. Because this assay
was performed on maternal whole-blood samples, as The most important conclusion from this study is that
there is a signiﬁcantly higher number of fetal cells pres-opposed to samples enriched for the presence of a spe-
ciﬁc fetal-cell type by a variety of cell-separation tech- ent in maternal blood when the fetus has trisomy 21.
Trisomy 21, which occurs in 1/1,000 births, is the mostniques, the fundamental question of how many fetal
cells were present in a starting sample could be ad- common autosomal aneuploidy among live borns that
results in serious mental retardation and congenitaldressed. This assay detected DNA derived from all fetal
nucleated cells in the sample, including trophoblasts, anomalies. The sixfold elevation in fetal cells observed
in the maternal circulation when the fetus had trisomyerythroblasts, lymphocytes, and granulocytes.
Our results indicate that male fetal DNA is detectable 21 should bode well for noninvasive cytogenetic screen-
ing for trisomy 21. This phenomenon is in agreementin 99.3% of pregnant women carrying male fetuses,
when a 16-ml blood sample is assayed. No unique with pathologic studies that demonstrate placental ab-
normalities such as immaturity and hydrops in cases ofmarker could be used to distinguish female fetal cells
from maternal cells in a similar PCR-based assay; how- trisomies 21, 13, and 18 (Labbe´ et al. 1989).
The other cases of aneuploidy represented in our data-ever, we assume that the same proportion of female
fetal cells would be detected in maternal blood if such base suggest that increased feto-maternal transfusion
also occurs in other fetal cytogenetic abnormalities, sucha marker were available.
In the fetuses with normal chromosomes, a highly as 47,XXY (Klinefelter syndrome) and 47,XY,/inv-
(dup)15. In our experience, cases of trisomy 18 weresigniﬁcant difference was observed in the number of
male fetal-cell DNA equivalents detected when the fetus the most variable in number of fetal cells detected. The
number of cases remains small, so no deﬁnitive conclu-was male versus when it was female. This database rep-
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